The company
Amgen Inc.
AMGN · Nasdaq
Health CareBiotechnologyLeading
AMGN stood above a rising 150-day average in 43 of the last 52 weekly readings, including each of the last 17 weeks. It is 13.8% above that average now. Biotechnology: 16% of its 561 stocks in an uptrend (−15 points in four weeks); Health Care: 26% (−10 points in four weeks).
Statistics
- Rotation
- Leading
- Weeks in an uptrend
- 17 in a row
- Industry in uptrend
- 16% -15 in 4 wk
- Insider buys, 12 months
- $0
- Insider sales, 12 months
- $55.0M
- Officials’ trades on record
- 183
In the rotation
Each square a week: lit when it closed above a rising 150-day average. 43 of 52 weeks.
20 Apr – 19 Oct
Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.
Money in and out
1 Nov 2024 – 1 Oct 2026
Open-market buys above the line and sales below, in dollars. Not yet read: institutions.
Congress and officials
183 disclosed lines: House 122, Senate 44, executive 17; 51 people.
| Who | Did | Amount | Traded |
|---|---|---|---|
| David J. Taylor House: U.S. House ClerkOH02 | bought | $1k–$15k | 22 Sep 2026filed 1 Oct 2026 |
| David J. Taylor House: U.S. House ClerkOH02 | sold | $1k–$15k | 26 Aug 2026filed 5 Sep 2026 |
| David J. Taylor House: U.S. House ClerkOH02 | sold | $1k–$15k | 26 Aug 2026filed 5 Sep 2026 |
| Sheldon Whitehouse Senate: U.S. Senate eFDSenator | sold part ofspouse | $1k–$15k | 12 Aug 2026filed 2 Sep 2026 |
| Donald J. Trump Executive branch: Office of Government EthicsWhite House Office | bought | $1k–$15k | 23 Jun 2026filed 22 Aug 2026 |
| Donald J. Trump Executive branch: Office of Government EthicsWhite House Office | bought | $15k–$50k | 12 Jun 2026filed 22 Aug 2026 |
| David J. Taylor House: U.S. House ClerkOH02 | bought | $1k–$15k | 5 Jun 2026filed 12 Jun 2026 |
| Donald J. Trump Executive branch: Office of Government EthicsWhite House Office | sold | $1k–$15k | 18 May 2026filed 1 Jul 2026 |
| Donald J. Trump Executive branch: Office of Government EthicsWhite House Office | bought | $100k–$250k | 15 May 2026filed 1 Jul 2026 |
| Donald J. Trump Executive branch: Office of Government EthicsWhite House Office | bought | $15k–$50k | 15 May 2026filed 1 Jul 2026 |
| Donald J. Trump Executive branch: Office of Government EthicsWhite House Office | sold | $1k–$15k | 11 May 2026filed 1 Jul 2026 |
| Donald J. Trump Executive branch: Office of Government EthicsWhite House Office | sold | $15k–$50k | 27 Apr 2026filed 1 Jul 2026 |
Insiders
Buy orders, 12 months0
Sale orders, 12 months10
Buyers · sellers0 · 6
| Who | Did | Shares | Traded |
|---|---|---|---|
| Rachna KhoslaSVP, Business Development | sold | 1,252at $416.43 | 13 Aug 2026filed 13 Aug 2026 |
| Rachna KhoslaSVP, Business Development | sold | 2,000at $412.57 | 11 Aug 2026filed 13 Aug 2026 |
| Nancy A. GrygielSVP & CCO | sold | 1,970at $402.16 | 6 Aug 2026filed 7 Aug 2026 |
| Nancy A. GrygielSVP & CCO | sold | 1,000at $402.16 | 6 Aug 2026filed 7 Aug 2026 |
| Derek MillerSVP, Human Resources | sold | 2,069at $402.54 | 6 Aug 2026filed 7 Aug 2026 |
| Derek MillerSVP, Human Resources | sold | 1,821at $402.54 | 6 Aug 2026filed 7 Aug 2026 |
| Nancy A. GrygielSVP & CCO | sold | 1,237at $323.73 | 4 May 2026filed 5 May 2026 |
| Esteban SantosEVP, Operations | sold | 30,501at $379.12 | 26 Feb 2026filed 2 Mar 2026 |
| Esteban SantosEVP, Operations | sold | 24,291at $379.12 | 26 Feb 2026filed 2 Mar 2026 |
| Matthew C. BuschVP, Finance & CAO | sold | 1,000at $375.79 | 19 Feb 2026filed 20 Feb 2026 |
Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.
Institutions
Still reading this part; it fills in a moment.
News
Amgen vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?fool.com · 20 Oct 2026Amgen vs. Bristol Myers Squibb: Which Healthcare Stock Is a Better Buy in 2026?fool.com · 20 Oct 2026Mattel Appoints Former Amgen CFO Peter Griffith as Finance Chiefeconotimes.com · 19 Oct 2026Amgen Has the Drugs and the Dividend. Now It Needs the Growthinsidermonkey.com · 19 Oct 2026Biogen (BIIB) vs Amgen (AMGN) and Gilead (GILD): Which Big Pharma Stock is a Better Buy?insidermonkey.com · 13 Oct 20261st Cir. Reinstates Migraine Drug Wrongful Death Action Against Amgenharrismartin.com · 12 Oct 2026Amgen (AMGN) and Johnson & Johnson (JNJ) Catch Jim Cramer's Eye for Different Reasonsinsidermonkey.com · 8 Oct 2026Amgen vs. Vertex Pharmaceuticals: Which Biotech Stock Is a Better Buy in 2026?fool.com · 4 Oct 2026
Everyone who traded it
Same industry
Government contracts
Awards4
Total$1.2B
Latest30 Sep 2022
TREATMENT FOR USE IN A MASS CASUALTY EVENT WHERE THROMBOCYTOPENIA OR PLATELET LOSS IS A MAJOR CONCERN.Department of Health and Human Services · $839.9M · 30 Sep 2022IGF::OT::IGF RTOR NUMBER: RTOR-CSF-0005 ACQUISITION OF COLONY STIMULATING FACTOR(S) (G-CSF OR GM-CSF) FOR MITIGATION OF NEUTROPENIA ARISING FROM EXPOSURE TO IONIZING RADIATIONDepartment of Health and Human Services · $154.4M · 13 Sep 2018IGF::OT::IGF FOR OTHER FUNCTIONS PROJECT: ACQUISITION OF COLONY STIMULATING FACTOR(S) (G-CSF OR GM-CSF) FOR MITIGATION OF NEUTROPENIA ARISING FROM EXPOSURE TO IONIZING RADIATION (RTOR-CSF-0003)Department of Health and Human Services · $37.7M · 30 Sep 2016IGF::OT::IGF TASK ORDER 1 UNDER RFP-12-100-SOL-00016Department of Health and Human Services · $157.3M · 25 Sep 2013
From its SEC filings
Analyst forecasts
No analyst forecasts yet.